keyword
MENU ▼
Read by QxMD icon Read
search

"Conjugated estrogen"

keyword
https://www.readbyqxmd.com/read/28185712/the-effect-of-selective-estrogen-receptor-modulators-on-type-2-diabetes-onset-in-women-basic-and-clinical-insights
#1
REVIEW
Beibei Xu, Dragana Lovre, Franck Mauvais-Jarvis
Selective estrogen receptor modulators (SERMs) are a class of compounds that interact with estrogen receptors (ERs) and exert agonist or antagonist effects on ERs in a tissue-specific manner. Tamoxifen, a first generation SERM, is used for treatment of ER positive breast cancer. Raloxifene, a second generation SERM, was used to prevent postmenopausal osteoporosis. The third-generation SERM bazedoxifene (BZA) effectively prevents osteoporosis while preventing estrogenic stimulation of breast and uterus. Notably, BZA combined with conjugated estrogens (CE) is a new menopausal treatment...
January 20, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/28132583/the-evolving-role-of-oral-hormonal-therapies-and-review-of-conjugated-estrogens-bazedoxifene-for-the-management-of-menopausal-symptoms
#2
Sharon J Parish, John A Gillespie
This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased the risk of invasive breast cancer after nearly 5 years of use...
January 30, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28101707/distributions-and-ecological-risk-assessment-of-estrogens-and-bisphenol-a-in-an-arid-and-semiarid-area-in-northwest-china
#3
Xiaowei Liu, Jianghong Shi, Ting Bo, Yaobin Meng, Xinmin Zhan, Mengtao Zhang, Yang Zhang
Free estrogens (estrone, E1; 17β-estradiol, 17β-E2; estriol, E3; and 17α-ethinylestradiol, EE2), their corresponding sulfate and glucuronide conjugates, and bisphenol A (BPA) were investigated in water and sediments in the Fen River catchment, an arid and semiarid area in northwest China. E1 and BPA were frequently detected in the wet and dry sampling seasons. In addition to the sulfate conjugates, other conjugated estrogens were not detected in water and sediments. The concentrations of these compounds in water generally increased from upstream to downstream...
January 18, 2017: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/27973466/treatment-of-menopausal-symptoms-new-era-with-new-options-or-new-options-for-menopausal-symptoms-after-15-years-of-whi-study
#4
Santiago Palacios, Pluvio J Coronado
Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene)...
December 14, 2016: Minerva Ginecologica
https://www.readbyqxmd.com/read/27916781/gradually-increasing-ethinyl-estradiol-for-turner-syndrome-may-produce-good-final-height-but-not-ideal-bmd
#5
Yukihiro Hasegawa, Daisuke Ariyasu, Masako Izawa, Junko Igaki-Miyamoto, Mami Fukuma, Megumi Hatano, Hiroko Yagi, Masahiro Goto
Estrogen replacement therapy in Turner syndrome should theoretically mimic the physiology of healthy girls. The objective of this study was to describe final height and bone mineral density (BMD) in a group of 17 Turner syndrome patients (group E) who started their ethinyl estradiol therapy with an ultra-low dosage (1-5 ng/kg/day) from 9.8˜13.7 years. The subjects in group E had been treated with GH 0.35 mg/kg/week since the average age of 7.4 years. The 30 subjects in group L, one of the historical groups, were given comparable doses of GH, and conjugated estrogen 0...
December 2, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27904630/a-survey-of-the-therapeutic-effects-of-vitamin-e-suppositories-on-vaginal-atrophy-in-postmenopausal-women
#6
Aazam Parnan Emamverdikhan, Nahid Golmakani, Sayyed ASajadi Tabassi, Malihe Hassanzadeh, Nooriyeh Sharifi, Mohammad Taghi Shakeri
BACKGROUND: Menopause is associated with various complications such as depression, sleep disorders, and genitourinary atrophy. Vaginal atrophy occurs due to the loss of steroid hormones, and its major symptoms include vaginal dryness, itching, dyspareunia, and bleeding after intercourse. According to the literature, vitamin E plays a key role in estrogen stability. The aim of this study was to compare the effects of vitamin E suppositories and conjugated estrogen vaginal cream on vaginal atrophy...
September 2016: Iranian Journal of Nursing and Midwifery Research
https://www.readbyqxmd.com/read/27853336/seventeen-alpha-hydroxylase-deficiency-associated-with-absent-gonads-and-myelolipoma-a-case-report-and-review-of-literature
#7
Mahmood Soveid, Ghanbar Ali Rais-Jalali
Congenital adrenal hyperplasia comprises a group of disorders resulting from defects in enzymes required for the synthesis of cortisol. The clinical presentation depends on the specific enzyme defect. We report a rare case of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. A 26-year-old female patient referred with hypertension and hypokalemia. She also had primary amenorrhea and lack of sexual development. The karyotype was 46, XY. Hormonal evaluation showed low serum levels of all steroid hormones, requiring alpha-hydroxylation, which included cortisol, 17 alpha-hydroxy progesterone, dehydroepiandrosterone sulfate, estradiol, and testosterone...
November 2016: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/27823739/direct-and-indirect-effects-of-conjugated-estrogens-bazedoxifene-treatment-on-quality-of-life-in-postmenopausal-women
#8
Lucy Abraham, Andrew G Bushmakin, Erika Dragon, Barry S Komm, JoAnn V Pinkerton
OBJECTIVE: Determine the direct and indirect effects of conjugated estrogens/bazedoxifene (CE/BZA) treatment on menopause-specific quality of life in a post-hoc analysis of 2 phase 3 Selective estrogens, Menopause, And Response to Therapy (SMART-1, SMART-2) trials. STUDY DESIGN: Data from participants in SMART-1 and SMART-2 who received CE 0.45mg/BZA 20mg, CE 0.625mg/BZA 20mg, or placebo were analyzed, including week 12 data from 1274 healthy postmenopausal women in SMART-1 and pooled week 1-4 and 9-12 data from 332 women with moderate to severe vasomotor symptoms (≥7 HFs/d or ≥50/wk) in SMART-2...
December 2016: Maturitas
https://www.readbyqxmd.com/read/27779568/longitudinal-changes-in-menopausal-symptoms-comparing-women-randomized-to-low-dose-oral-conjugated-estrogens-or-transdermal-estradiol-plus-micronized-progesterone-versus-placebo-the-kronos-early-estrogen-prevention-study
#9
Nanette Santoro, Amanda Allshouse, Genevieve Neal-Perry, Lubna Pal, Rogerio A Lobo, Frederick Naftolin, Dennis M Black, Eliot A Brinton, Matthew J Budoff, Marcelle I Cedars, N Maritza Dowling, Mary Dunn, Carey E Gleason, Howard N Hodis, Barbara Isaac, Maureen Magnani, JoAnn E Manson, Virginia M Miller, Hugh S Taylor, Whitney Wharton, Erin Wolff, Viola Zepeda, S Mitchell Harman
OBJECTIVE: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. METHODS: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E2) 50 μg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275)...
October 24, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27749740/comparison-of-pueraria-mirifica-gel-and-conjugated-equine-estrogen-cream-effects-on-vaginal-health-in-postmenopausal-women
#10
Narathorn Suwanvesh, Jittima Manonai, Areepan Sophonsritsuk, Wichai Cherdshewasart
OBJECTIVES: To compare the effects of a 12-week treatment with Pueraria mirifica (PM) gel or a conjugated estrogen cream on vaginal maturation index, vaginal symptom score, vaginal health assessment score, and vaginal flora in postmenopausal women. METHODS: In a prospective, noninferiority, randomized controlled study, 82 postmenopausal women with at least one vulvovaginal symptom, that is, dryness, soreness, irritation, dyspareunia, or discharge, were recruited...
February 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27676118/pooled-analysis-of-the-effects-of-conjugated-estrogens-bazedoxifene-on-vasomotor-symptoms-in-the-selective-estrogens-menopause-and-response-to-therapy-trials
#11
David F Archer, Ellen W Freeman, Barry S Komm, Kelly A Ryan, Ching-Ray Yu, Sebastian Mirkin, JoAnn V Pinkerton
OBJECTIVES: Conjugated estrogens/bazedoxifene (CE/BZA) reduced menopause-related hot flashes (HFs) in the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. This post hoc pooled analysis of SMART-1 and -2 further characterized effects of CE/BZA on HFs in the overall population and patient subgroups. METHODS: Data from two randomized, double-blind, placebo- and active-controlled, phase 3 studies were pooled for nonhysterectomized postmenopausal women with moderate/severe HFs given CE 0...
November 2016: Journal of Women's Health
https://www.readbyqxmd.com/read/27650094/a-multi-center-randomized-controlled-and-open-clinical-trial-of-heyan-kuntai-capsule-and-hormone-therapy-in-perimenopausal-women
#12
Ai-Jun Sun, Ya-Ping Wang, Bei Gu, Ting-Ping Zheng, Shou-Qing Lin, Wen-Pei Bai, Yang Wei, Shao-Fen Zhang, Ying Zhang
OBJECTIVE: To evaluate the efficacy and safety of Heyan Kuntai Capsule (, HYKT) and hormone therapy (HT) on perimenopausal syndromes (PMSs). METHODS: From 2005 to 2008, 390 women with PMSs were recruited from 4 clinic centers. The inclusion criteria included ages 40 to 60 years, estradiol (E2) below 30 ng/L, and follicle stimulating hormone (FSH) above 40 IU/L, etc. The patients were randomly assigned to HYKT group or HT group by random number table method, administrated HYKT or conjugated estrogen with/without medroxyprogesterone acetate tablets for 12 months...
September 20, 2016: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/27631562/ce-bza-effects-on-bone-and-quality-of-life-in-european-postmenopausal-women-a-pooled-analysis
#13
P Hadji, K A Ryan, C-R Yu, S Mirkin, Barry S Komm
OBJECTIVES: To evaluate the efficacy of conjugated estrogens/bazedoxifene (CE/BZA) on bone mineral density (BMD), bone turnover markers (BTM), and menopause-specific quality of life (MENQOL) in European women. METHODS: Data through 12 months were pooled from two double-blind, randomized, controlled trials in non-hysterectomized postmenopausal women who received CE/BZA or placebo. Women from European study sites with evaluable BMD (n = 60), BTM (n = 56), and MENQOL questionnaire (n = 236) data were included and compared with 1523 women from US study sites (n = 730 with evaluable data for bone outcomes)...
October 2016: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/27524190/-analysis-of-the-effects-on-menopausal-symptoms-quality-of-life-and-cardiovascular-risk-factors-of-five-different-therapy-in-women-at-early-stage-of-menopause
#14
W Xue, A J Sun, T P Zheng, J F Jiang, Y P Wang, Y Zhang, F L Chen, Y Deng, Y F Wang
OBJECTIVE: To explore the effects of five different therapy in women at early stage of menopause on menopausal symptoms, quality of Life and cardiovascular risk factors. METHODS: A total of 140 women at early stage of menopause were randomly divided into five groups. Thirty women took Conjugated estrogen and medroxyprogesterone acetate(CEE+ MPA) sequential therapy, 27 women took estradiol valerate and medroxyprogesterone acetate(E2V+ MPA) sequential therapy, 26 women took estradiol valerate and Progesterone Soft Capsules(E2V+ P) sequential therapy, 30 women took Kuntai capsule, and 27 took Cohosh extract...
August 2, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/27437306/comparison-of-the-effects-of-vaginal-royal-jelly-and-vaginal-estrogen-on-quality-of-life-sexual-and-urinary-function-in-postmenopausal-women
#15
Fatemeh Seyyedi, Mahmoud Rafiean-Kopaei, Sepideh Miraj
INTRODUCTION: Several causes can disturb the quality of life in postmenopausal women. Stress, urinary incontinence is one of the factors that can influence the quality of life of women, since they evade social activities and limit their behavior. Vulvovaginal disorders adversely impacts sexual action, psychosocial health, and partner relationships. AIM: The aim of this study was to examine the therapeutic properties of vaginal cream of royal jelly and estrogen on quality of life, sexual and urinary problems in postmenopausal women...
May 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27433860/timing-and-persistence-of-effect-of-conjugated-estrogens-bazedoxifene-in-postmenopausal-women
#16
Risa Kagan, Barry S Komm, Kelly A Ryan, Joanne Lavenberg, Ching-Ray Yu, JoAnn V Pinkerton
OBJECTIVE: The aim of the study was to determine the time course of effect with conjugated estrogens/bazedoxifene (CE/BZA) in nonhysterectomized postmenopausal women in five phase 3 trials. METHODS: This post hoc analysis identified when CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg first achieved a statistically significant difference (P < 0.05) versus placebo in individual trials and the duration the difference persisted for prespecified efficacy endpoints...
July 18, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27427235/effect-of-short-term-estrogen-therapy-on-endothelial-function-a-double-blinded-randomized-controlled-trial
#17
R Hurtado, M Celani, S Geber
OBJECTIVE: To evaluate the effect of short-term hormone replacement therapy with 0.625 mg conjugated estrogens daily on endothelial function of healthy postmenopausal women, using flow-mediated dilation (FMD) of the brachial artery. METHODS: We performed a double-blinded, randomized, controlled trial over 3 years. Randomization was performed using computer-generated sorting. All participants were blinded to the use of conjugated equine estrogens (CEE) or placebo and FMD was assessed by a blinded examiner, before and after 28 days of medication...
October 2016: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/27404034/effect-of-conjugated-estrogens-bazedoxifene-on-postmenopausal-bone-loss-pooled-analysis-of-two-randomized-trials
#18
J Christopher Gallagher, Santiago Palacios, Kelly A Ryan, Ching-Ray Yu, Kaijie Pan, David L Kendler, Sebastian Mirkin, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene reduces vasomotor symptoms and prevents postmenopausal bone loss without stimulating the breast and endometrium. We analyzed changes in bone mineral density (BMD) and bone markers using pooled data from two phase-3 trials. METHODS: Selective Estrogens, Menopause, and Response to Therapy (SMART)-1 and SMART-5 were randomized, double-blind, placebo- and active-controlled studies conducted in postmenopausal nonhysterectomized women...
October 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27404028/relationship-between-changes-in-vasomotor-symptoms-and-changes-in-menopause-specific-quality-of-life-and-sleep-parameters
#19
JoAnn V Pinkerton, Lucy Abraham, Andrew G Bushmakin, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: This study characterizes and quantifies the relationship of vasomotor symptoms (VMS) of menopause with menopause-specific quality of life (MSQOL) and sleep parameters to help predict treatment outcomes and inform treatment decision-making. METHODS: Data were derived from a 12-week randomized, double-blind, placebo-controlled phase 3 trial that evaluated effects of two doses of conjugated estrogens/bazedoxifene on VMS in nonhysterectomized postmenopausal women (N = 318, mean age = 53...
October 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27404026/most-bothersome-symptom-in-women-with-genitourinary-syndrome-of-menopause-as-a-moderator-of-treatment-effects
#20
JoAnn V Pinkerton, Andrew G Bushmakin, Lucy Abraham, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) is indicated to treat moderate/severe menopausal vasomotor symptoms and prevent postmenopausal osteoporosis. This analysis examines the impact of the most bothersome vaginal symptom at baseline on effects of CE/BZA. METHODS: This post hoc analysis used data from a 12-week clinical trial of nonhysterectomized postmenopausal women (n = 664) randomly assigned to double-blind treatment with CE/BZA (0.45/20 mg and 0...
October 2016: Menopause: the Journal of the North American Menopause Society
keyword
keyword
65784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"